This product is no longer in stock
Treatment of oncologic diseases
Embryo and foetotoxic effect of Hycamtin have shown in experimental studies. As other cytotoxic agents, Hycamtin may adversely affect the fetus in the appointment of pregnant women.
It is necessary to advise women to use reliable methods of contraception during Hycamtin therapy and immediately inform the treating physician if pregnancy occurs. It is not known whether the medicine appears in breast milk, so in the period of treatment is recommended to stop breast-feeding.
Long-term use does not cause an increase in the toxic effect of the medicine. Serious manifestations of cardiotoxicity, neurotoxicity, organ toxicity were not observed.
From hemopoiesis system: very often - neutropenia, febrile neutropenia, leukopenia, thrombocytopenia, and anemia; often - pancytopenia; rarely - pronounced bleeding due to thrombocytopenia.
Immune system: often - hypersensitivity reactions, including rash.
From the digestive system: very often - diarrhea, nausea, vomiting (including severe) pain in the abdomen, constipation, stomatitis, anorexia (including severe); often - hyperbilirubinemia.
Skin: very often - alopecia.
Others: very often - fever, fatigue, asthenia, accession secondary infections; often - weakness, sepsis; very rarely - ecchymosis, hemorrhage (mild and did not require specific treatment).
Also known as: Topotecan Hydrochloride for Injection, Topotec, Topocan, Topotel, Toranex, Topotecan Actavis, Verotekan, Potactasol